Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation
- 20 April 2022
- journal article
- research article
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 146, 105526
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A ReviewOncology Research and Treatment, 2013
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- An overview of the c-MET signaling pathwayTherapeutic Advances in Medical Oncology, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerJournal of Clinical Oncology, 2011
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197Journal of Biological Chemistry, 2011
- Chemistry in Second LifeBMC Chemistry, 2009
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Electrostatics of nanosystems: Application to microtubules and the ribosomeProceedings of the National Academy of Sciences, 2001